Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Nivolumab with ipilimumab for previously untreated locally advanced non-small-cell lung cancer	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Nivolumab with ipilimumab adjuvant therapy for renal cell carcinoma	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Nivolumab in combination with ipilimumab in addition to chemotherapy for treating non-small cell lung cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Nivolumab in combination with ipilimumab for the adjuvant treatment of melanoma	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Melanoma	Skin Cancer	2019	View \| Download
Nivolumab in combination with Ipilimumab for Recurrent or Metastatic Head and Neck Cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Head and neck cancer	Head and Neck Cancer	2018	View \| Download
Nivolumab in combination with ipilimumab for previously untreated unresectable or metastatic urothelial cancer – first-line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Urothelial cancer	Urological Cancer	2020	View \| Download
Nivolumab in combination with ipilimumab for oesophageal squamous cell carcinoma – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download
Nivolumab in combination with ipilimumab for malignant pleural mesothelioma – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2019	View \| Download
Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastric cancer	Gastrointestinal Cancer	2021	View \| Download